Journal article · 2025 · Open access
Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease
EngMedicine, 2(3), 100088 · Published 3 July 2025 · DOI 10.1016/j.engmed.2025.100088
In brief
“Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease” is a 2025 journal article by Xingtao Zhao and 5 co-authors, published in EngMedicine. OpenAlex counts 14 citations as of 21 November 2026, which puts it in the top 8% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at EngMedicine.
- Citations
- 14
- Most cited in
- 2026 (12)
- Field-weighted impact
- 2.74
- References
- 164
- Authors
- 6
Abstract
Cholestatic liver disease (CSLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are both associated with abnormal bile acid (BA) metabolism and have a steadily increasing incidence and prevalence worldwide. BAs are amphiphilic cholesterol metabolites that are pivotal in the regulation of their own biosynthesis as well as gut microbiota, indirectly affecting both host immunity and metabolic homeostasis. Conversely, the composition and function of BAs, including their reabsorption and excretion, are regulated by gut microbiota. Thus, regulating gut microbiota or targeting BA metabolic pathways is expected to provide novel strategies for the treatment of liver diseases. The present review focuses on elucidating the critical roles of the gut microbiota-BA axis in CSLD and MASLD and its potential as a therapeutic target. First, we clarify the roles of gut microbiota, BAs, and BA receptors, mainly farnesoid X receptor (FXR) and G protein-coupled BA receptor 1 (TGR5), in the modulation of hepatic glucose, lipid, and amino acid metabolism and intestinal barrier function, which effectively maintains the balance of the host immunoinflammatory response, as well as different cell death pathways. We also summarize recent preclinical and clinical studies involving the gut microbiota-BA axis. Subsequently, we emphasize the indirect regulation of BA metabolism by targeting gut microbiota through dietary interventions, fecal microbiota transplantation (FMT), and bacteriophage therapy and direct regulation of BA signaling by targeting secondary BAs, BA receptor agonists (fibroblast growth factor [FGF]19/21), and inhibitors of BA transporters (apical sodium-dependent BA transporter [ASBT], sodium taurocholate co-transporting polypeptide [NTCP]). Finally, we summarize and discuss mainly nanoparticle-based therapeutic strategies for modulating BA metabolism and the composition and function of the gut microbiota. Therefore, this review provides new insights to better understand the gut microbiota-BA axis in the context of treating CSLD and MASLD. • The gut microbiota modulates BAs to regulate hepatic metabolism. • Diversity of BA modifications affect the intestinal microenvironment. • Targeting the gut-BA axis could lead to promising treatments for CSLD and MASLD.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhao, X., Li, R., Sun, R., Pan, Q., Lu, H., & Chai, J. (2025). Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease. EngMedicine, 2(3), 100088. https://doi.org/10.1016/j.engmed.2025.100088
MLA 9
Zhao, Xingtao, et al. “Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease.” EngMedicine, vol. 2, no. 3, 2025, p. 100088. https://doi.org/10.1016/j.engmed.2025.100088.
Chicago
Zhao, Xingtao, Ruolan Li, Ruiqi Sun, Qiong Pan, Hongyan Lu, and Jin Chai. 2025. “Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease.” EngMedicine 2 (3): 100088. https://doi.org/10.1016/j.engmed.2025.100088.
Harvard
Zhao, X. et al. (2025) ‘Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease’, EngMedicine, 2(3), p. 100088. doi:10.1016/j.engmed.2025.100088.
IEEE
X. Zhao, R. Li, R. Sun, Q. Pan, H. Lu, and J. Chai, “Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease,” EngMedicine, vol. 2, no. 3, p. 100088, 2025, doi: 10.1016/j.engmed.2025.100088.
BibTeX
@article{zhao2025targeting,
title = {{Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease}},
author = {Zhao, Xingtao and Li, Ruolan and Sun, Ruiqi and Pan, Qiong and Lu, Hongyan and Chai, Jin},
journal = {EngMedicine},
year = {2025},
volume = {2},
number = {3},
pages = {100088},
doi = {10.1016/j.engmed.2025.100088},
url = {https://doi.org/10.1016/j.engmed.2025.100088}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- cholestatic liver disease
- non-alcoholic fatty liver disease
- bile acid metabolism
- farnesoid X receptor
- TGR5
- bile acid receptors
- ASBT
- normal tissue complication probability
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Zhao, X., Li, R., Sun, R., Pan, Q., Lu, H., & Chai, J. (2025). Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease. EngMedicine, 2(3), 100088. https://doi.org/10.1016/j.engmed.2025.100088
How many times has this paper been cited?
14 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at EngMedicine: sign in and open the full text from this page.
Who wrote this paper?
Xingtao Zhao, Ruolan Li, Ruiqi Sun, Qiong Pan, Hongyan Lu, Jin Chai.
What is the DOI of this paper?
10.1016/j.engmed.2025.100088, permanently at https://doi.org/10.1016/j.engmed.2025.100088. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.